https://doi.org/10.4081/hmr.v2i5.733

New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 155
PDF: 552
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S Amadori
support@pagepress.org
The CD33 antigen is a 67-kD sialic acid-dependent adhesion protein that is specific for myeloid cells. CD33 is expressed on approximately 90% of AML cases, as defined by the presence of the antigen on greater than 20% of the leukemic blasts, but not on normal CD34+ pluripotent hematopoietic stem cells or nonhematopoietic tissues.1 Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized IgG4 anti-CD33 monoclonal antibody (hP67.6). The hP67.6 antibody is non-cytotoxic by itself.2 In vitro data indicate that when GO binds the CD33 antigen, the complex is rapidly internalized.3,4 Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell by acid hydrolysis. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death by apoptosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Amadori, S. (2009). New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.733
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).